As of 2024-12-12, the EV/EBITDA ratio of Oxford BioMedica PLC (OXB.L) is -12.76. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. OXB.L's latest enterprise value is 479.66 mil GBP. OXB.L's TTM EBITDA according to its financial statements is -37.58 mil GBP. Dividing these 2 quantities gives us the above OXB.L EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 6.8x - 13.6x | 12.1x |
| Forward P/E multiples | 8.6x - 17.3x | 16.5x |
| Fair Price | (332.84) - (511.57) | (536.49) |
| Upside | -177.9% - -219.8% | -225.6% |
| Date | EV/EBITDA |
| 2024-12-05 | -12.71 |
| 2024-12-04 | -12.78 |
| 2024-12-03 | -12.78 |
| 2024-12-02 | -12.72 |
| 2024-11-29 | -12.80 |
| 2024-11-28 | -12.80 |
| 2024-11-27 | -12.71 |
| 2024-11-26 | -12.71 |
| 2024-11-25 | -12.69 |
| 2024-11-22 | -12.57 |
| 2024-11-21 | -12.36 |
| 2024-11-20 | -12.36 |
| 2024-11-19 | -12.36 |
| 2024-11-18 | -12.28 |
| 2024-11-15 | -12.26 |
| 2024-11-14 | -12.36 |
| 2024-11-13 | -12.52 |
| 2024-11-12 | -12.72 |
| 2024-11-11 | -12.52 |
| 2024-11-08 | -12.36 |
| 2024-11-07 | -12.48 |
| 2024-11-06 | -12.44 |
| 2024-11-05 | -12.51 |
| 2024-11-04 | -12.23 |
| 2024-11-01 | -12.14 |
| 2024-10-31 | -11.95 |
| 2024-10-30 | -12.24 |
| 2024-10-29 | -12.16 |
| 2024-10-28 | -12.69 |
| 2024-10-25 | -13.27 |
| 2024-10-24 | -12.59 |
| 2024-10-23 | -12.73 |
| 2024-10-22 | -12.51 |
| 2024-10-21 | -12.43 |
| 2024-10-18 | -11.88 |
| 2024-10-17 | -11.22 |
| 2024-10-16 | -10.98 |
| 2024-10-15 | -11.54 |
| 2024-10-14 | -11.74 |
| 2024-10-11 | -11.60 |
| 2024-10-10 | -11.60 |
| 2024-10-09 | -11.58 |
| 2024-10-08 | -11.62 |
| 2024-10-07 | -11.50 |
| 2024-10-04 | -11.58 |
| 2024-10-03 | -11.44 |
| 2024-10-02 | -11.44 |
| 2024-10-01 | -11.48 |
| 2024-09-30 | -11.32 |
| 2024-09-27 | -11.48 |